Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled time : 14:20 save search
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
Published: 2023-07-26 (Crawled : 14:20) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
abbvie preclinical collaboration
Genmab Announces Financial Results for the First Quarter of 2023
Published: 2023-05-10 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.92%
H: 0.54%
C: -0.64%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.24%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.03%
H: 0.26%
C: 0.01%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.09%
H: 0.48%
C: 0.28%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.21%
H: 0.32%
C: -0.07%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.15%
H: 2.12%
C: 1.79%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.6%
H: 1.64%
C: -0.39%
financial results
The Global ELISA Market to Showcases Growth at a Significant CAGR of ~6% by 2027 | DelveInsight
Published: 2023-04-06 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.36%
H: 2.91%
C: 2.91%
CRL | $226.78 -0.34% 0.0% 410K
|
Commercial Services
|
| O: -0.08%
H: 0.55%
C: 0.52%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.86%
C: 0.47%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
EXAS | $60.97 -3.95% -4.12% 2.2M
|
Health Technology
|
| O: -0.82%
H: 3.93%
C: 3.85%
global growth market
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
Published: 2023-01-16 (Crawled : 14:20) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
agreement
AbbVie, Anima Strike mRNA Deal Worth Up to $582
Published: 2023-01-10 (Crawled : 14:20) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.35%
H: 0.12%
C: -1.6%
deal mrna
Cosmetic Surgery Market Report 2022-2032
Published: 2022-11-23 (Crawled : 14:20) - prnewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.29%
H: 0.72%
C: -2.46%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.1%
H: 0.62%
C: -0.35%
SIEN | $0.174 0.69% 3.4M
|
Health Technology
|
| O: 0.0%
H: 6.67%
C: -1.93%
report market
The Worldwide Enzyme Replacement Therapy Industry is Expected to Reach $15 Billion by 2028
Published: 2022-09-16 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.15%
H: 1.04%
C: 0.15%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.62%
H: 1.01%
C: 0.46%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.95%
H: 1.21%
C: 1.1%
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -0.91%
H: 0.18%
C: -2.12%
expected therapy
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
Motley Rice, LLC Announces Class Action in the AbbVie Inc. Securities Litigation
Published: 2022-05-16 (Crawled : 14:20) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
Bronstein, Gewirtz & Grossman, LLC Notifies AbbVie, Inc. (ABBV) Investors of Class Action and Encourages Investors to Contact the Firm
Published: 2022-04-08 (Crawled : 14:20) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.16%
H: 1.68%
C: 1.13%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.